Related Experiment Video
Updated: Jul 10, 2026
06:19
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Published on: July 18, 2017
CD40-induced countercurrent conduits for tumor escape or elimination?
Gopal Murugaiyan1, Sunil Martin, Bhaskar Saha
1National Centre for Cell Science, Ganeshkhind, Pune 411007, India.
Trends in Immunology
|November 6, 2007
Summary
CD40 signaling promotes blood vessel growth, which can aid tumor spread but also allow anti-tumor cells to enter. Harnessing this dual role for cancer immunity requires further investigation.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- CD40 is a receptor on immune and endothelial cells, binding CD40-ligand on T cells.
- CD40 signaling influences both pro-inflammatory and anti-inflammatory responses.
- Vascular endothelial growth factor, a mediator of CD40 signaling, promotes angiogenesis.
Purpose of the Study:
- To explore the dual role of CD40-mediated angiogenesis in tumor immunity.
- To investigate how newly formed capillaries impact tumor metastasis and anti-tumor cell infiltration.
Main Methods:
- Analysis of CD40 expression on endothelial and antigen-presenting cells.
- Investigation of CD40 signaling pathways and mediator production.
- Evaluation of the impact of angiogenesis on tumor cell metastasis and effector cell entry.
Main Results:
- CD40 signaling induces mediators like vascular endothelial growth factor, promoting new blood vessel formation (angiogenesis).
- These new vessels can facilitate tumor cell metastasis.
- The same vessels may also serve as entry points for anti-tumor immune cells.
Conclusions:
- CD40-induced angiogenesis presents a paradox in cancer immunity, potentially aiding tumor spread while also enabling anti-tumor immune cell access.
- Further research is needed to understand how to manipulate these countercurrent processes to enhance anti-tumor immunity.
